You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
研報掘金丨開源證券:維持海思科“買入”評級,估值有望迎來新一輪提升
格隆匯 04-15 15:31

開源證券研報指出,海思科(002653.SZ)24年歸母淨利潤3.95億元(+34.00%),麻醉鎮痛穩增長,創新管線強驅動,維持“買入”評級。環泊酚成爲最大產品,銷售收入同比增幅約45%。創新藥倍長平和思美寧上市第一年收入達數千萬元,將成爲2025年業績增長的主力軍。公司建立豐富的產品管線組合,環泊酚擴展兒童/青少年用藥的補充申請正在審評;美國方面“全麻誘導”適應症已完成PNDA 溝通交流。呼吸系統藥物HSK31858 片的“非囊性纖維化支氣管擴張症”適應症已啓動國內Ⅲ期。公司創新轉型成長可期,估值有望迎來新一輪提升。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account